Iodine 125 prostate brachytherapy: Prognostic factors for long-term urinary, digestive and sexual toxicities

被引:5
|
作者
Doyen, J. [1 ]
Chamorey, E. [2 ]
Ali, A. Mohammed [1 ]
Ginot, A. [1 ]
Ferre, M. [1 ]
Castelli, J. [1 ]
Quintens, H. [3 ]
Amiel, J. [3 ]
Hannoun-Levi, J. -M. [1 ]
机构
[1] Ctr Antoine Lacassagne, Dept Radiotherapie Oncol, F-06189 Nice, France
[2] Ctr Antoine Lacassagne, Unite Stat Med, F-06189 Nice, France
[3] CHU Pasteur, Serv Urol, F-06002 Nice 1, France
来源
CANCER RADIOTHERAPIE | 2009年 / 13卷 / 08期
关键词
Complications; Brachytherapy; Prostate cancer; 125; Iodine; Implant; Prognostic factors; LATE RECTAL FUNCTION; QUALITY-OF-LIFE; INTERSTITIAL BRACHYTHERAPY; (125)IODINE IMPLANTATION; BIOCHEMICAL OUTCOMES; I-125; BRACHYTHERAPY; PREDICTIVE FACTORS; SEED IMPLANTATION; TUMOR-CONTROL; MORBIDITY;
D O I
10.1016/j.canrad.2009.08.144
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. - For patients with good urinary function and presenting with a low risk prostate cancer, prostate brachytherapy using iodine implants represents one of the techniques of reference. This retrospective analysis investigates urinary (U), digestive (D) and sexual (S) toxicities and their prognostic factors of duration. Material and methods. - From August 2000 to November 2007, 176 patients presenting with prostate adenocarcinoma underwent interstitial brachytherapy. Urinary, digestive and sexual toxicities were classified according to Common toxicities criteria for adverse events, version 3.0 (CTCAE V3.0). For each toxicity (U. D, S), the number of complications U (dysuria, nicturia ...), D (proctitis, diarrhea ...) and S (sexual dysfunction, loss of libido ....) was listed and analyzed according to criteria related to the patient, implant, dosimetric data and characteristics of the toxicity. Prognostic factors identified in univariate analysis (UVA) (Log Rank) were further analyzed in multivariate analysis (MVA) (Cox model). Results. - With a median follow-up of 26 months (1-87), 147 patients (83.5%) presented urinary toxicities. Among them, 29.5% (86 patients) and 2.4% (seven patients) presented grade 2 and 3 U toxicity respectively. In UVA, urinary grade toxicity greater than or equal to 2 (p=0.037), the presence of initial U symptoms (p=0.027) and more than two urinary toxicities (p=0.00032) were recognized as prognostic factors. The number of U toxicities was the only prognostic factor in MVA (p=0.04). D toxicity accounted for 40.6% (71 patients). Among them, 3% (six patients) were grade 2. None were grade 3. Two factors were identified as prognostic factors either in UVA and MVA: the number of D toxicities greater than or equal to 2 (univariate analysis: p=0.00129, multivariate analysis: p=0,002) and age less than or equal to 65 years (univariate analysis: p=0,004, multivariate analysis: p=0,007). Eighty-three patients (47.4%) presented a sexual toxicity: 26.9% (49 patients) and 5% (nine patients) were scored as grade 2 and 3 respectively. A number of seeds greater than 75 (p=0.032) and S grade greater than or equal to 2 (p < 0.0001) were recognized as prognostic factors in UVA. S grade was the only prognostic factor in MVA (p=0.0015). Conclusion. - The duration of U, D and S toxicity is strongly correlated with a high number of toxicities and the grade of toxicity. This analysis allows for better information given to the patient regarding the duration of the post-treatment complications. (C) 2009 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:721 / 730
页数:10
相关论文
共 50 条
  • [1] Long-term urinary sequelae following 125iodine prostate brachytherapy
    Crook, Juanita
    Fleshner, Neil
    Roberts, Chris
    Pond, Greg
    JOURNAL OF UROLOGY, 2008, 179 (01): : 141 - 145
  • [2] Long-term urinary sequelae following 125iodine prostate brachytherapy -: Comment
    Miller, David C.
    JOURNAL OF UROLOGY, 2008, 179 (01): : 146 - 146
  • [3] Long term urinary sequelae following iodine 125 prostate brachytherapy
    Crook, J.
    Fleshner, N.
    Roberts, C.
    Pond, G.
    RADIOTHERAPY AND ONCOLOGY, 2007, 84 : S16 - S16
  • [4] Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years
    Stone, Nelson N.
    Stock, Richard G.
    UROLOGY, 2007, 69 (02) : 338 - 342
  • [5] Factors influencing long-term urinary symptoms after prostate brachytherapy
    Stone, Nelson N.
    Winoker, Jared S.
    Kaplan, Steven A.
    Stock, Richard G.
    BJU INTERNATIONAL, 2018, 122 (05) : 831 - 836
  • [6] Preimplant predictive factors of urinary retention after iodine 125 prostate Brachytherapy
    Mabjeesh, Nicola J.
    Chen, Juza
    Stenger, Amira
    Matzkin, Haim
    UROLOGY, 2007, 70 (03) : 548 - 553
  • [7] Sexual function following iodine 125 prostate brachytherapy
    Crook, J.
    Webster, D.
    Virtue, D.
    RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S41 - S41
  • [8] Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy
    Keyes, Mira
    Pickles, Tom
    Crook, Juanita
    McKenzie, Michael
    Cheung, Arthur
    Spadinger, Ingrid
    LaPointe, Vincent
    Bachand, W. Francois
    Morris, James
    BRACHYTHERAPY, 2015, 14 (03) : 334 - 341
  • [9] LONG-TERM URINARY SYMPTOMS FOLLOWING PROSTATE BRACHYTHERAPY
    Stone, Nelson
    Winoker, Jared
    Cavallo, Jamie
    Kaplan, Steven
    Stock, Richard
    JOURNAL OF UROLOGY, 2017, 197 (04): : E41 - E41
  • [10] LONG-TERM URINARY FUNCTION AFTER PROSTATE BRACHYTHERAPY
    Leapman, Michael
    Stock, Richard
    Hall, Simon
    Mock, Stephen
    Stone, Nelson
    NEUROUROLOGY AND URODYNAMICS, 2013, 32 (02) : 119 - 120